

Neuronetrix

November 11, 2013
FOR IMMEDIATE RELEASE:

Contact:
Daniel Lawson
Neuronetrix
1044 E. Chestnut St.
Louisville KY 40204
(502) 561-9040, x7003
dlawson@neuronetrix.com
www.neuronetrix.com

Signature HealthCARE signs letter of intent to use Neuronetrix's COGNISION™ System at 27 special care facilities.

Louisville, KY (November 11, 2013) — [Neuronetrix](http://www.neuronetrix.com) today announced that it has received a signed Letter of Intent from Signature HealthCARE, LLC, to purchase COGNISION™ Systems for use at 27 special care facilities throughout the US. Signature HealthCARE's Serenity division plans to use the neurodiagnostic devices as a key part of the dementia care services provided to their elderly residents.

[Serenity HealthCARE](http://www.signaturehealthcare.com) works with several leading universities to provide specialized care to individuals suffering from Alzheimer's disease and other forms of dementia. These collaborations help Serenity to continually evaluate and establish new and more effective practices in dementia care.

Serenity will use the COGNISION™ Systems to test individuals for cognitive or memory problems. They will also use the systems to evaluate novel non-pharmacological interventions which might improve outcomes for Serenity's special needs residents.

"This agreement represents a major commitment from Signature to provide advanced clinical services for their elderly clients as well as tremendous validation of our COGNISION™ System," said K.C. Fadem, CEO of Neuronetrix, "and as Signature continues to expand its regional coverage and service offerings, Neuronetrix will continue to grow along with them."

About COGNISION™

The COGNISION™ System is a proprietary, neurodiagnostic device which enables objective assessments of cognitive function using a non-invasive technology called [event-related potentials](#) (ERP).

About Neuronetrix

Neuronetrix is a leading neurodiagnostic company focused on revolutionizing the diagnosis of patients with neurologic disorders by providing accurate and meaningful diagnostic information to physicians early in the disease process.

Information about Neuronetrix is available at <http://www.neuronetrix.com> or by contacting Daniel Lawson at dlawson@neuronetrix.com, or (502) 561-9040, x7003.

